Press Release
RepliCel to Commence Trading on the TSX Venture Exchange
11 years ago
Jan 08, 2014 
VANCOUVER, BC – January 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CSE: RP) is pleased to announce that its common shares are anticipated to commence trading on the TSX Venture Exchange (the “TSXV”) on January 13, 2014 as a Tier 1 issuer. RepliCel will trade under its current trading symbol “RP”. To ensure continued and seamless trading for RepliCel’s shareholders, RepliCel’s common shares will be delisted from the Canadian Securities Exchange at the close of trading on January 10, 2014 and will commence trading on the TSXV at market open on January 13, 2014.
About RepliCel Life Sciences
RepliCel is a clinical stage biopharmaceutical company focused on developing autologous cell therapies. RepliCel Tendon-01 (RCT-01) is a cell therapy for the treatment of chronic tendon injuries. RepliCel Hair-01 (RCH-01) is a cellular treatment for androgenetic alopecia (pattern baldness). Shiseido Company, Limited has an exclusive geographic license for RCH-01 in certain Asian countries including Japan, China and South Korea. Both product candidates are based on RepliCel’s innovative technology which utilizes cells isolated from a patient’s own healthy hair follicles to address specific cellular deficits. For additional information please visit www.replicel.com.
On Behalf of the Board
RepliCel Life Sciences Inc.
/s/ David Hall
David Hall
President and Chief Executive Officer
COMPANY CONTACT:
Tammey George, Director of Communications
RepliCel Life Sciences
604-248-8696
tg@replicel.com
INVESTOR CONTACTS:
Westwicke Partners, LLC
Stefan Loren, Ph.D., Managing Director
(443) 213-0507
sloren@westwicke.com
Robert H. Uhl, Managing Director
(858) 356-5932
robert.uhl@westwicke.com
Notice Regarding Forward Looking Statements
This press release contains projections and forward-looking statements as that term is defined under applicable securities laws. Statements in this press release that are not purely historical are forward-looking statements, which include statements regarding the date of listing on the TSXV and delisting from the Canadian Securities Exchange. These statements are only predictions and involve known and unknown risks which may cause actual results and RepliCel’s plans and objectives to differ materially from those expressed in the forward-looking information, including: unforeseen delays in the listing and delisting of RepliCel’s common shares and other factors beyond the Company’s control.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
by Topic
DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.